Trial Profile

A Phase I/II clinical study of NR082 in Leber Hereditary Optic Neuropathy in US.

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esonadogene imvoparvovec (Primary)
Indications Leber's hereditary optic atrophy
Focus Therapeutic Use

Most Recent Events

23 Feb 2024 New trial record
19 Feb 2024 According to a Neurophth Therapeutics media release, Status changed to active, no longer recruiting.
19 Feb 2024 According to Neuropth media release, the company announced that the last patient has been enrolled and dosed in Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND4 mutation (ND4-LHON) in the U.S.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com